Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + mitomycin C
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of everolimus (RAD001), an mTOR inhibitor, and mitomycin C, an antibiotic with antineoplastic properties. This combination has been studied in clinical trials for treating various cancers, particularly metastatic esophagogastric cancer. In a phase I trial for metastatic esophagogastric cancer, it showed encouraging signs of antitumor activity. The recommended dose from phase I trials was everolimus 10 mg/day combined with intravenous mitomycin C 5 mg/m² every 3 weeks.
- Other names
- RAD001 + Mitomycin CRAD001 + MitomycinC
02
Targets
DNATXNRD2 (Thioredoxin reductase 2)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on everolimus + mitomycin C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + mitomycin C.